Targets › CD117
1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on CD117, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Actinium Pharmaceuticals | Iomab-B Anti-CD117 monoclonal antibody conjugated to iodine-131 | CD117 | Phase 3 | Acute Myeloid Leukemia; Non Hodgkin Lymphoma | Dec 2026 |
Acute Myeloid Leukemia (1) Non Hodgkin Lymphoma (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.